RNS Number : 3432L
Akers Biosciences, Inc.
08 January 2009
8 January 2009-Correction
The following amended text replaces RNS Number:3247L issued at 12.00 today.
Akers Biosciences Inc.
Grant of Warrants
Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the grant of warrants over a total of 2,110,000 common shares of nil par value to the following Directors:
|
Director
|
Exercise Price (p)
|
Number of warrants
|
Resultant holding of warrants
|
|
|
|
|
|
|
Thomas A. Nicolette
|
12
|
500,000
|
4,050,000
|
|
Edward Mulhare
|
12
|
500,000
|
844,000
|
|
Raymond Akers
|
12
|
500,000
|
5,550,000
|
|
Daniel Seckinger
|
12
|
500,000
|
932,000
|
|
Charles Bunker
|
12
|
110,000
|
110,000
|
The warrants are exercisable immediately and have a 10 year term.
Enquiries:
Thomas A. Nicolette
President and CEO
Tel. +1 856 848 8698
Ben Simons
M: Communications
Tel. +44 (0)20 7153 1540
Alasdair Younie
Arbuthnot Securities Limited
Tel. +44 (0)20 7012 2000
About Akers Biosciences
Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSUUUGCGUPBGWR